Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Zoloft · 2 trials · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| 2 | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Zoloft® 100 mg Tablets | DRUG | 1 x 100 mg, single-dose fed |
| Sertraline hydrochloride 100 mg Tablets | DRUG | 1 x 100 mg, single-dose fed |
Inclusion Criteria: * Subjects will be females and/or males, non-smokers, 18 years of age and older. Female subjects will be post-menopausal or surgically sterilized. * Post-menopausal status is defined as absence of menses for the past 12 months. * Sterile status is defined as hysterectomy, bilate...
Zoloft is a small molecule drug being developed by Teva Pharmaceutical Industries Limited for use in healthy volunteers. It is currently in Phase 1 clinical development, with studies evaluating the drug in healthy individuals. The drug is not approved for any specific indication and remains investigational.
Zoloft is being developed by Teva Pharmaceutical Industries Limited, a company traded under the ticker TEVA. The drug is currently in Phase 1 clinical trials, with studies conducted in Canada. Teva is responsible for the development and clinical testing of this investigational drug.
Zoloft is currently in Phase 1 clinical development. It has completed two Phase 1 trials, with a total enrollment of 42 participants. The drug is investigational and has not been approved by regulatory authorities. All completed trials were active-controlled, though they were not double-blinded.
Zoloft has been studied in two completed Phase 1 clinical trials. The first trial, NCT00836667, evaluated Sertraline Hydrochloride 100 mg tablets under fed conditions in 18 healthy volunteers. The second trial, NCT00836849, evaluated the same tablets under fasting conditions in 24 participants. Both trials were conducted in Canada.
Zoloft is the brand name for sertraline hydrochloride, as indicated by the clinical trial titles that use the name Sertraline Hydrochloride. The drug is being developed by Teva Pharmaceutical Industries Limited and is currently in Phase 1 trials for healthy volunteers. It is an investigational small molecule drug.